A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbiditiesCapsule Summary

• Asıl Yazarlar: Dea Metko, BSc (Yazar), Maha Alkofide, MD (Yazar), Mohannad Abu-Hilal, MD, MRCP (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Elsevier, 2024-06-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: Dupilumab is a monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (MtS-AD). Various clinical trials have established the effectiveness and safety of dupilumab for the treatment MtS-AD; however, the real-world experiences of patients treated with dupilu...